To get a sense of who is truly in control of Silence Therapeutics plc (NASDAQ:SLN), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of ...

A fourth ex-US Coast Guard cutter has been transferred to the Sri Lanka Navy, US Ambassador to Sri Lanka, Julie Chung, said yesterday. Posting on X, Chung said the vessel will embolden Sri Lanka’s ...

One thing we could say about the analysts on Silence Therapeutics plc (NASDAQ:SLN) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

The web framework for Python is already celebrating its 20th birthday. A new study shows which JavaScript libraries are most frequently combined with it. The Django Software Foundation and the team ...

The Python Software Foundation (PSF) has withdrawn a grant application submitted earlier this year to the US government. Specifically, the PSF had applied to the National Science Foundation of the US ...

A Florida woman has emerged as the ultimate grand prize winner of a python-removal challenge, earning $10,000 after removing 60 Burmese pythons during the 10-day competition. On Aug. 13, the Florida ...

Sentinel lymph node (SLN) biopsy for early cervical cancer achieved non-inferiority versus pelvic lymphadenectomy, according to results of a large randomized study from China. Patients assigned to SLN ...

SXSW: Snake hunters from around the world descend upon the Everglades to cull the invasive Burmese python population in a contest that plays out like a Florida-fied "Cannonball Run." You can’t have a ...

EXCLUSIVE: Slithering into SXSW this afternoon at the Alamo Lamar, The Python Hunt is a documentary that might do for the Burmese Python what Jaws did 50 years ago for the Great White Shark. The ...

Goldman Sachs initiated Silence Therapeutics (NASDAQ:SLN) with a Sell rating and a $6 price target on Tuesday, arguing that with only about $173M of cash and equivalents at the end of Q3 2024, the U.K ...

Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Silence Therapeutics (SLN – Research Report) today and set a price target of $49.00. The company’s shares closed last Friday at $17.99.